GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Net Margin %

Cytokinetics (Cytokinetics) Net Margin % : -8,187.56% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cytokinetics's Net Income for the three months ended in Dec. 2023 was $-136.90 Mil. Cytokinetics's Revenue for the three months ended in Dec. 2023 was $1.67 Mil. Therefore, Cytokinetics's net margin for the quarter that ended in Dec. 2023 was -8,187.56%.

The historical rank and industry rank for Cytokinetics's Net Margin % or its related term are showing as below:

CYTK' s Net Margin % Range Over the Past 10 Years
Min: -6988.63   Med: -321.57   Max: 15.46
Current: -6988.63


CYTK's Net Margin % is ranked worse than
88.73% of 1029 companies
in the Biotechnology industry
Industry Median: -162.58 vs CYTK: -6988.63

Cytokinetics Net Margin % Historical Data

The historical data trend for Cytokinetics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Net Margin % Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -452.93 -228.00 -305.72 -411.21 -6,988.63

Cytokinetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,019.93 -2,846.07 -14,837.02 -34,238.62 -8,187.56

Competitive Comparison of Cytokinetics's Net Margin %

For the Biotechnology subindustry, Cytokinetics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Net Margin % falls into.



Cytokinetics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cytokinetics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-526.244/7.53
=-6,988.63 %

Cytokinetics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-136.896/1.672
=-8,187.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytokinetics  (NAS:CYTK) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Cytokinetics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (Cytokinetics) Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Executives
Robert I Blum officer: EVP, Corp. Development & CBO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik officer: SVP Research & Early Dev 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong officer: VP, Chief Accounting Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw officer: SVP Finance & CFO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa director
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington director C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg officer: SVP - Legal & General Counsel C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg officer: V.P., Human Resources 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044